Remedy Cell Announces Initiation of Phase 1b Clinical Trial of RC-0315 in IPF Patients
Haifa, Israel — Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, today announces the initiation of “A partially-blinded randomized Phase 1b single and repeat dose (4-cohort) safety & tolerability study of RC-0315/Placebo administered intra-bronchially to idiopathic pulmonary fibrosis patients”. The primary objective of the RC-0315 First-in-Human, Phase…

